Abstract
Due to design flaws and disappointing progression-free survival data in CodeBreaK 200, a confirmatory phase III trial for the KRASG12C inhibitor sotorasib, the drug's full approval as a second-line option for metastatic KRASG12C non-small cell lung cancer may be delayed and will likely hinge on further studies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
